Immutep Limited (IMMP)
1.83
0.01 (0.55%)
At close: Mar 28, 2025, 11:52 AM
0.55% (1D)
| Bid | 1.82 |
| Market Cap | 266.37M |
| Revenue (ttm) | 591.75K |
| Net Income (ttm) | -6.73M |
| EPS (ttm) | -0.21 |
| PE Ratio (ttm) | -8.71 |
| Forward PE | -12.33 |
| Analyst | Buy |
| Ask | 1.84 |
| Volume | 6,911 |
| Avg. Volume (20D) | 74,246 |
| Open | 1.82 |
| Previous Close | 1.82 |
| Day's Range | 1.78 - 1.84 |
| 52-Week Range | 1.65 - 3.34 |
| Beta | 1.98 |
About IMMP
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, wh...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 19, 2012
Employees 41
Stock Exchange NASDAQ
Ticker Symbol IMMP
Website https://www.immutep.com
Analyst Forecast
According to 2 analyst ratings, the average rating for IMMP stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 364.48% from the latest price.
Stock Forecasts4 months ago
+11.76%
Immutep shares are trading higher after the compan...
Unlock content with
Pro Subscription
6 months ago
-12.5%
Immutep shares are trading lower. The company announced efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha in combination with MSD's anti-PD-1 therapy KEYTRUDA as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients.
